Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

405

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

December 15, 2018

Conditions
Breast Cancer
Interventions
DRUG

UTD1 Injection plus capecitabine

DRUG

Capecitabine

Trial Locations (11)

100021

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

100071

The Hospital Affiliated To Military Medical Science, Beijing

100853

The General Hospital of the People's Liberation Army, Beijing

110001

the First Hospital of China Medical University, Shenyang

110042

Liaoning Cancer Hospital & Institute, Shenyang

150081

Harbin Medical University Cancer Hospital, Harbin

200433

Fudan University Shanghai Cancer Center, Shanghai

310016

Sir Run Run Shaw Hospital, Hangzhou

310022

Zhejiang Cancer Hospital, Hangzhou

450008

Henan Cancer Hospital, Zhengzhou

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Beijing Biostar Pharmaceuticals Co., Ltd.

INDUSTRY